What we must know about EDTA

The FDA approved EDTA for its metal-binding ability but has since issued the following warning: “The two EDTA drugs have established names that are easily confused and both are referred to in clinical practice as "EDTA." This confusion has resulted in medication errors in which some patients have received the wrong drug, which has been fatal in some cases or caused serious adverse reactions in others. The error is especially dangerous when edetate disodium is erroneously given to a patient who is supposed to receive edetate calcium disodium.
The two EDTA drugs have different approved uses and significantly different effects. Risks are low when infusion protocols are followed.

Chelation Article Response

Summary of the response to Dr. Michael Gerber's article "Thirty Years of Progress in Cardiovascular Heath", Townsend Letter Oct 2011: view

  • Studies indicate NaMgEDTA is successful in treating atherosclerotic disease.
  • EDTA is not a suitable chelating substance for mercury
  • In its oral form, EDTA only detoxifies the digestive tract
  • As a suppository, EDTA detoxifies the colon.
  • EDTA, provided orally or as a suppository, does not cause clinically or statistically significant metal binding within the blood stream.

TACT: Surprising, puzzling benefit from chelation therapy after MI

Los Angeles, CA (updated) - A randomized, double-blind trial of chelation therapy has suggested that the alternative-medicine mainstay may modestly improve clinical outcomes in patients after an acute MI, leaving its own investigators and other knowledgeable observers scratching their heads.

Read more